Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
May 10, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
April 26, 2022 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Key Commercial Team Appointments
April 12, 2022 08:30 ET
|
Cellectar Biosciences
Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances David Lasecki Appointed Executive Director, Strategic Alliances FLORHAM PARK, N.J., April 12, 2022 (GLOBE NEWSWIRE) --...
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
March 21, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Participate at Upcoming Banking Conferences
March 10, 2022 16:05 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Announces Executive Leadership Changes
February 23, 2022 08:00 ET
|
Cellectar Biosciences
Names Mr. Chad Kolean as Chief Financial Officer Promotes Mr. Jarrod Longcor to Chief Operating Officer FLORHAM PARK, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:...
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
January 04, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
December 13, 2021 08:30 ET
|
Cellectar Biosciences
Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma Mean ORR of 45.5%, CBR of 72.7% and DCR of 100% and the subset of quad/penta drug refractory patients...
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
December 08, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
November 16, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...